Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.

Scientific reports - 13 Jul 2016

George Angela, Riddell Daniel, Seal Sheila, Talukdar Sabrina, Mahamdallie Shazia, Ruark Elise, Cloke Victoria, Slade Ingrid, Kemp Zoe, Gore Martin, Strydom Ann, Banerjee Susana, Hanson Helen, Rahman Nazneen

Abstract excerpt

Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15% of ovarian cancer patients have a germline BRCA1 or BRCA2 mutation which has substantial implications for their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Cost-Benefit Analysis

Share to Genetic Testing

Share to Neoplasms

Share to Patient Satisfaction

Share to Surveys and Questionnaires

Source

Open in PubMed Open full text

Identifiers

PMID: 27406733
DOI: 10.1038/srep29506
PMCID: PMC4942815

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.PMID 27406733Read ↗

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patientsSemantic proximity Read ↗

Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer.Semantic proximity Read ↗

A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.Semantic proximity Read ↗

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.Semantic proximity Read ↗

Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testingSemantic proximity Read ↗

Mainstreamed genetic testing for women with ovarian cancer: first-year experience.Semantic proximity Read ↗

Cascade testing in an ovarian cancer traceback genetic testing program: The GRACE study experience.Semantic proximity Read ↗

Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their managementSemantic proximity Read ↗

Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing.Semantic proximity Read ↗

Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspectiveSemantic proximity Read ↗

Mainstreamed genetic testing in ovarian cancer: patient experience of the testing processSemantic proximity Read ↗

Routine germline genetic testing in 3552 unselected NHS breast cancer patients: Evidence informing testing criteria and implementation of a ‘BRCA-DIRECT’ mainstreaming pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.